Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
159 GBX | 0.00% | 0.00% | -12.88% |
May. 21 | Transcript : Arecor Therapeutics plc - Special Call | |
May. 20 | Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins | CI |
Sales 2023 | 4.57M 5.82M | Sales 2024 * | 7.49M 9.52M | Capitalization | 48.7M 61.95M |
---|---|---|---|---|---|
Net income 2023 | -8M -10.18M | Net income 2024 * | -5M -6.36M | EV / Sales 2023 | 12.2 x |
Net cash position 2023 * | 6.16M 7.84M | Net cash position 2024 * | 1.46M 1.86M | EV / Sales 2024 * | 6.31 x |
P/E ratio 2023 |
-6.52
x | P/E ratio 2024 * |
-9.09
x | Employees | 51 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 48.52% |
Latest transcript on Arecor Therapeutics plc
1 month | +15.64% | ||
3 months | +20.00% | ||
6 months | -16.32% | ||
Current year | -12.88% |
Managers | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 49 | 14-12-31 |
Susan Lowther
DFI | Director of Finance/CFO | 65 | 18-12-31 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 07-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 78 | 21-04-12 |
Christine Soden
BRD | Director/Board Member | 66 | 21-04-30 |
Andrew Richards
CHM | Chairman | 64 | 21-04-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 159 | 0.00% | 2,000 |
24-06-06 | 159 | 0.00% | 12,784 |
24-06-05 | 159 | 0.00% | 11,590 |
24-06-04 | 159 | 0.00% | 11,722 |
24-06-03 | 159 | 0.00% | 15,676 |
Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.88% | 61.96M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- AREC Stock